港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

英派藥業-B

13.020

+0.0700.54%

成交量：617.86萬

成交額：8,436.49萬

市值：36.78億

市盈率：-10.06

高：14.500

開：13.290

低：12.820

收：12.950

52周最高：47.980

52周最低：10.310

股本：2.82億

香港流通股本：2.82億

量比：2.25

換手率：2.19%

股息：- -

股息率：- -

每股收益(LYR):-1.295

淨資產收益率：--

總資產收益率：-40.35%

市淨率：4.04

市盈率(LYR):-10.06

市銷率: 26.49

資料載入中...

總覽公司新聞資訊公告

《業績》英派藥業(07630.HK)中期虧損收窄至9,081萬元人民幣

阿斯达克财经

英派藥業-B2026年上半年營收1.05億元，經調整淨虧損0.21億元

英派藥業-B(07630.HK)發布中期業績收入1.05億元按年增長316.8%

英派藥業－Ｂ(07630)股價顯著波動13.301%，現價港幣$15.52

阿斯达克财经

英派藥業－Ｂ(07630)股價下跌5.201%，現價港幣$12.76

阿斯达克财经

英派藥業-B(07630.HK)獲納入恒生綜合指數成份股

英派藥業-B(07630)獲納入恒生綜合指數有望成為港股通標的

英派藥業-B定於8月31日召開董事會審議2026年中期未審計業績

英派藥業－Ｂ(07630)股價下跌8.197%，現價港幣$12.32

阿斯达克财经

醫藥股局部走強海西新藥（02637）上漲8.98% 機構指AI製藥進展率先帶動生命科學上游需求

港股異動 | 英派藥業-B(07630)升逾3% 預期中期取得虧損按年減少約22%至37% 已將IMP2794提名為PPC

英派藥業-B（07630）首款自研KAT6A高特異性PROTAC IMP2794獲選為臨床前候選化合物

英派藥業-B(07630)提名IMP2794為臨床前候選化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特異性PROTAC

營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發

深圳商报·读创

英派藥業(07630.HK)料中期虧損按年減少最多約37%

阿斯达克财经

英派藥業-B預計中期營收最高增逾三倍虧損顯著收窄

英派藥業-B(07630.HK)預期中期取得虧損約8170萬元至9990萬元按年減少約22%至37%

英派藥業－Ｂ(07630)股價下跌5.054%，現價港幣$12.21

阿斯达克财经

英派藥業-B7月股份變動月報：股本保持穩定

港股異動 | 英派藥業-B(07630)午後跌超13% 7月初至今累跌近七成總市值已不足35億港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/07630/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派藥業-B","latestPrice":13.02,"timestamp":1792138094538,"preClose":12.95,"halted":0,"volume":6178600,"delay":0,"changeRate":0.005405405405405427,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"重陽節翌日休市","change":0.07,"latestTime":"10-16 16:08:14","open":13.29,"high":14.5,"low":12.82,"amount":84364938,"amplitude":0.12973,"askPrice":13.02,"askSize":3400,"bidPrice":12.97,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.95,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":2.2529243603096694,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.294715,"volumeRatio":2.2529243603096694,"shares":282461530,"dividePrice":0,"high":14.5,"amplitude":0.12973,"preClose":12.95,"low":12.82,"week52Low":10.31,"pbRate":"4.04","psRate":"26.49","week52High":47.98,"institutionHeld":0,"latestPrice":13.02,"committee":-0.888889,"eps":-1.294715,"divideRate":0,"volume":6178600,"delay":0,"ttmEps":-1.052,"open":13.29,"prevYearClose":20.1,"prevWeekClose":13.02,"prevMonthClose":14.07,"prevQuarterClose":14.07,"fiveDayClose":12.68,"twentyDayClose":11.28,"sixtyDayClose":12.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782403200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-10-15","current":-12.376426,"percent":0.607477,"low":-34.323153,"twenty":-29.852178,"median":-13.23402,"eighty":-10.652923,"high":-8.821219,"avg":-17.72259,"sd":8.718874,"marketCap":3657876813},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649},{"date":"2026-08-28","current":-12.490535,"twenty":-30.224959,"median":-15.896725,"eighty":-10.316459,"marketCap":4310937679},{"date":"2026-09-04","current":-14.62831,"twenty":-30.072679,"median":-15.691688,"eighty":-10.353511,"marketCap":4403575252},{"date":"2026-09-11","current":-12.087934,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"marketCap":3643753737},{"date":"2026-09-18","current":-12.193817,"twenty":-29.977617,"median":-13.665771,"eighty":-10.535977,"marketCap":3680473735},{"date":"2026-09-25","current":-12.65778,"twenty":-29.936332,"median":-13.862539,"eighty":-10.54718,"marketCap":3813230655},{"date":"2026-10-02","current":-13.309453,"twenty":-29.921275,"median":-13.342238,"eighty":-10.553476,"marketCap":4013778341},{"date":"2026-10-09","current":-11.861614,"twenty":-29.878786,"median":-13.325845,"eighty":-10.610057,"marketCap":3581612200},{"date":"2026-10-15","current":-12.092826,"twenty":-29.852178,"median":-13.23402,"eighty":-10.652923,"marketCap":3657876813}],"updateTime":1792419300413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663075261","title":"《業績》英派藥業(07630.HK)中期虧損收窄至9,081萬元人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075261","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663075261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 16:46","pubTimestamp":1788165960,"startTime":"0","endTime":"0","summary":"英派药业(07630.HK) 公布2026年6月底止六个月中期业绩，收入1.0519亿元人民币(下同)，按年升316.8%。亏损由上年同期1.2873亿元收窄至9,081万元，每股亏损0.37元。不派息。(su)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205163848553_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205163848553_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542186/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542186/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["CNHmain","BK1161","UCmain","07630","MCNHmain","MUCmain","CYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167736412","title":"英派藥業-B2026年上半年營收1.05億元，經調整淨虧損0.21億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167736412","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167736412?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 16:38","pubTimestamp":1788165480,"startTime":"0","endTime":"0","summary":"2026年上半年，英派药业-B实现营收1.05亿元，同比增长316.8%。同期，经调整净亏损为0.21亿元，较去年同期的0.56亿元显著收窄62.6%。公司毛利率为90.8%，上年同期为97.7%；经营活动所得现金流净额为0.24亿元，较上年同期的0.30亿元减少0.06亿元。销售及分销开支为0.23亿元，上年同期该指标约为0.05亿元。英派药业-B执行董事兼首席执行官蔡遂雄博士：“本人谨代表董事会衷心感谢股东及业务合作伙伴一直以来的信任及支持，亦感谢雇员的勤勉、奉献、忠诚及诚信。”","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英派药业-B2026年上半年营收1.05亿元，经调整净亏损0.21亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507581","title":"英派藥業-B(07630.HK)發布中期業績 收入1.05億元 按年增長316.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663507581?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 16:34","pubTimestamp":1788165294,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722336","title":"英派藥業－Ｂ(07630)股價顯著波動13.301%，現價港幣$15.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722336","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722336?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 10:53","pubTimestamp":1787799180,"startTime":"0","endTime":"0","summary":"[异动股]英派药业－Ｂ(07630) 股价在上午10:52出现显著波动13.301%，现股价为港币$15.52，比前收市价上升8.078%8.078%。至目前为止，今日最高价为$15.52，而最低价为$13.61。总成交量为37.6万股，总成交金额为港币$558.223万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112134428668_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112134428668_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260827279/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260827279/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661247970","title":"英派藥業－Ｂ(07630)股價下跌5.201%，現價港幣$12.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2661247970","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661247970?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 10:44","pubTimestamp":1787539440,"startTime":"0","endTime":"0","summary":"[下跌股]英派药业－Ｂ(07630) 股价在上午10:43比前收市价下跌5.201%，现股价为港币$12.76。至目前为止，今日最高价为$13.7，而最低价为$12.76。总成交量为11.7万股，总成交金额为港币$156.18万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608243651/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608243651/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241386","title":"英派藥業-B(07630.HK)獲納入恒生綜合指數成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241386","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661241386?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 07:57","pubTimestamp":1787529422,"startTime":"0","endTime":"0","summary":"格隆汇8月24日丨英派药业-B(07630.HK)发布公告，其已获恒生指数有限公司选定并将纳入恒生综合指数成份股，自2026年9月7日起生效。获纳入恒生综合指数成份股后，公司股份预期将符合纳入沪港通及深港通交易的标准。沪港通及深港通是香港与中国内地资本市场投资者进行股票交易及投资的渠道。\r\n\r\n　　公司认为，其获纳入恒生综合指数成份股，表明国际资本市场对公司的行业地位、经营表现及整体价值的认可。预期此举将提升股票的交易流动性，扩大并多元化股东基础，并有助于公司的长期持续增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260824/32344064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["07630","HSCI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661601562","title":"英派藥業-B(07630)獲納入恒生綜合指數 有望成為港股通標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661601562","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661601562?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 19:54","pubTimestamp":1787313252,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年8月21日，恒生指数公司公布截至2026年6月30日之恒生指数系列季度检讨结果，其中英派药业-B获纳入恒生综合指数。恒生综合指数变动将于9月4日(星期五)收市后实施并于9月7日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。英派药业有可能被调入港股通，因其满足了包括市值、流动性等在内的一系列标准。英派药业今日大涨超10%，收报13.46港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCI","07630","FLHK","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101909160","title":"英派藥業-B定於8月31日召開董事會審議2026年中期未審計業績","url":"https://stock-news.laohu8.com/highlight/detail?id=1101909160","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101909160?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:42","pubTimestamp":1787128928,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（07630）8月19日在港交所公告称，公司董事会将于2026年8月31日（星期一）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。\n公告显示，截至本公告日期，公司董事会由3名执行董事、3名非执行董事及3名独立非执行董事组成。执行董事包括蔡遂雄博士（兼首席执行官）、田野博士及马宁女士；非执行董事为徐聪博士、Qiang Xu博士及刘涛先生；独立非执行董事为郭明博士、萧志雄先生及邵黎明博士。\n公司提醒投资者关注相关业绩公告发布时间，并据此评估可能产生的影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411860","title":"英派藥業－Ｂ(07630)股價下跌8.197%，現價港幣$12.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411860","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660411860?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 11:25","pubTimestamp":1787109900,"startTime":"0","endTime":"0","summary":"[下跌股]英派药业－Ｂ(07630) 股价在上午11:25比前收市价下跌8.197%，现股价为港币$12.32。至目前为止，今日最高价为$13.42，而最低价为$12.32。总成交量为22.7万股，总成交金额为港币$286.594万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608192317/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608192317/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660102783","title":"醫藥股局部走強 海西新藥（02637）上漲8.98% 機構指AI製藥進展率先帶動生命科學上游需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2660102783","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660102783?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 13:50","pubTimestamp":1786945800,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股局部走强，海西新药 上涨8.98%、凯莱英上涨7.95%、英派药业-B上涨7.71%、昭衍新药上涨6.86%、金斯瑞生物科技上涨6.83%、现代中药集团上涨5.95%东吴证券表示，AI制药进展率先带动生命科学上游需求。上游需求端，基因合成、蛋白表达与纯化、体外验证、模式动物等环节均因AI候选分子爆发而系统性受益，其中公司预计TwistAI相关订单预计从2500万美元跃升至1亿美元量级，金斯瑞生物科技一体化蛋白表达服务迎来高速增长。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988436","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","BK1576","02637","09939","07630","159938","BK1161","BK1191","HK0000320223.HKD","VTHR","01477","01643","QTOC","HK0000306701.USD","BK1515","06127","BK1583","HK0000306685.HKD","06821","ARTY","BK1141","BK1574","BK1606","AIPO","CHAT","01548","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659118951","title":"港股異動 | 英派藥業-B(07630)升逾3% 預期中期取得虧損按年減少約22%至37% 已將IMP2794提名為PPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118951","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659118951?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 13:48","pubTimestamp":1786686502,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B涨超3%，截至发稿，涨2.64%，报12.43港元，成交额306.36万港元。此外，英派药业-B公告称，公司已将IMP2794提名为临床前候选化合物，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4588","PPC","07630","KCAI","BK4212","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111945504","title":"英派藥業-B（07630）首款自研KAT6A高特異性PROTAC IMP2794獲選為臨床前候選化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1111945504","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111945504?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 17:20","pubTimestamp":1786526458,"startTime":"0","endTime":"0","summary":"2026年8月12日，英派药业-B公布，其已正式将IMP2794提名为临床前候选化合物。IMP2794为一款针对KAT6A的高特异性蛋白降解靶向嵌合体，系公司依托自有靶向蛋白降解平台发现的首个PCC。公告披露，IMP2794可高效、选择性地降解KAT6A，对同源蛋白KAT6B的选择性超过1,000倍。英派药业-B提醒，根据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证最终能够成功开发、制造及／或商业化IMP2794。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658780479","title":"英派藥業-B(07630)提名IMP2794為臨床前候選化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特異性PROTAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658780479","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658780479?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 17:17","pubTimestamp":1786526237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，英派药业已将IMP2794提名为临床前候选化合物，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。IMP2794是一种高效且选择性作用于KAT6A的降解剂，对KAT6B的选择性超过1000倍。IMP2794在敏感、非敏感乳腺癌CDX模型中均展现出优异的体内抗肿瘤效果。同时，对KAT6B的抑制与潜在的血液毒性相关。公司已建立依托E3配体库与连接子库的降解平台，可快速组装口服生物利用度优异的PROTAC分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B(07630)提名IMP2794为临床前候选化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特异性PROTAC","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2658911994","title":"營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["07630","EIKN","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995580","title":"英派藥業(07630.HK)料中期虧損按年減少最多約37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995580","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995580?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 16:49","pubTimestamp":1786438140,"startTime":"0","endTime":"0","summary":"英派药业(07630.HK) 预计，截至2026年6月30日止六个月收入约9,470万元至1.16亿元人民币(下同)，按年增加约276%至359%；期内亏损约8,170万元至9,990万元，按年减少约37%至22%。(ha/)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260508093246273_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260508093246273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537625/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537625/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170386983","title":"英派藥業-B預計中期營收最高增逾三倍 虧損顯著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1170386983","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170386983?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 16:47","pubTimestamp":1786438063,"startTime":"0","endTime":"0","summary":"英派药业-B8月11日发布盈利预告称，预计截至2026年6月30日止六个月的收入约94.7百万元至约1.16亿元，较2025年同期的25.2百万元增长约276%至359%。同期公司预计录得期内亏损约81.7百万元至99.9百万元，较上一年度同期的128.7百万元减少约37%至22%。\\n\\n英派药业-B预计将在2026年8月公布中期业绩。公司提醒投资者在买卖公司证券时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899307","title":"英派藥業-B(07630.HK)預期中期取得虧損約8170萬元至9990萬元 按年減少約22%至37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899307?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 16:47","pubTimestamp":1786438054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658096545","title":"英派藥業－Ｂ(07630)股價下跌5.054%，現價港幣$12.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2658096545","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658096545?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:45","pubTimestamp":1786412700,"startTime":"0","endTime":"0","summary":"[下跌股]英派药业－Ｂ(07630) 股价在上午09:45比前收市价下跌5.054%，现股价为港币$12.21。至目前为止，今日最高价为$12.8，而最低价为$12.21。总成交量为5.5万股，总成交金额为港币$68.481万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260811384/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260811384/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120585564","title":"英派藥業-B7月股份變動月報：股本保持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120585564","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120585564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:25","pubTimestamp":1785921932,"startTime":"0","endTime":"0","summary":"英派药业-B（股票代码：07630）于2026年8月5日发布了截至2026年7月31日的证券变动月报表。报告显示，公司上月底已发行普通股（H股）总数为282,461,530股，本月无增加或减少，月末结存仍为282,461,530股。注册股本保持人民币282,461,530元，且未有任何库存股份变动。公司指出，目前已满足香港联交所对于公众持股量的相关要求。\n报告并未披露任何股份期权或股权激励计划的授出、行使或失效事件，亦无新增发行、购回或注销股份记录。公司股本结构在本月维持不变。公告由执行董事兼首席执行官蔡遂雄签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656323387","title":"港股異動 | 英派藥業-B(07630)午後跌超13% 7月初至今累跌近七成 總市值已不足35億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656323387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656323387?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 14:09","pubTimestamp":1785737359,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B午后跌超13%，截至发稿，跌12.47%，报11.58港元，成交额527.74万港元。英派药业最高可收获总计4.235亿欧元款项。值得注意的是，市场此前普遍预测，因为英派药业满足港股通市值要求，将于2026年9月顺利纳入港股通。据悉，本次9月港股通调整，6月30日收盘市值是考核基准。然而考核落地后该股快速杀跌，7月2日暴跌45%，此后股价继续阴跌。截至8月3日，市值已不足35亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","KCAI","BK4588","07630","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":123,"code":"91000000","status":"200"}]}}